Edition:
United States

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

4.50USD
14 Dec 2017
Change (% chg)

$0.14 (+3.21%)
Prev Close
$4.36
Open
$4.41
Day's High
$4.77
Day's Low
$4.33
Volume
18,315
Avg. Vol
14,222
52-wk High
$28.69
52-wk Low
$3.52

Chart for

About

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's... (more)

Overall

Beta: --
Market Cap(Mil.): $71.96
Shares Outstanding(Mil.): 15.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414

Dec 05 2017

BRIEF-Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution

* Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​

Nov 07 2017

BRIEF-Novan acquires IP rights to treat viral malignancies with nitric oxide

* Novan acquires IP rights to treat viral malignancies with nitric oxide

Oct 18 2017

BRIEF-Novan Inc says files for mixed shelf of upto $150 million ‍​

* Novan Inc says files for mixed shelf of upto $150 million - SEC filing‍​ ‍​

Oct 02 2017

BRIEF-Machelle Sanders appointed to Novan board of directors

* Machelle Sanders appointed to Novan board of directors Source text for Eikon: Further company coverage:

Sep 26 2017

BRIEF-Novan conducts guidance meeting with FDA on SB204 development program

* Novan conducts guidance meeting with FDA on SB204 development program

Sep 25 2017

BRIEF-Novan Inc director ‍Robert Ingram reports open market purchase of 12,000 shares of co's common stock - SEC filing​

* Novan Inc director ‍Robert Ingram reports open market purchase of 12,000 shares of co's common stock - SEC filing​

Aug 29 2017

BRIEF-Novan, interim CFO William Hodges enter into an amendment to offer letter

* Novan Inc - on June 28, co and William L. Hodges, interim CFO of company, entered into an amendment to offer letter dated March 21, 2017 - SEC filing

Jun 29 2017

Earnings vs. Estimates